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Abstract
Histopathological classification of human tumors relies in part on the degree of differentiation of the tumor sample. To date,
there is no objective systematic method to categorize tumor subtypes by maturation. In this paper, we introduce a novel
computational algorithm to rank tumor subtypes according to the dissimilarity of their gene expression from that of stem
cells and fully differentiated tissue, and thereby construct a phylogenetic tree of cancer. We validate our methodology with
expression data of leukemia, breast cancer and liposarcoma subtypes and then apply it to a broader group of sarcomas. This
ranking of tumor subtypes resulting from the application of our methodology allows the identification of genes correlated
with differentiation and may help to identify novel therapeutic targets. Our algorithm represents the first phylogeny-based
tool to analyze the differentiation status of human tumors.
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Introduction
Cancer research has traditionally focused on the identification
of oncogenes and tumor suppressor genes, but in the last decades it
has become increasingly apparent that disruption of normal
differentiation is an important component of tumorigenesis. Lack
of cellular maturation is now recognized as a hallmark of human
cancers [1], and the degree of differentiation of a tumor is
important for diagnosis, prognosis, and treatment. Investigations
of hematopoietic malignancies, for instance, have benefited
considerably from an understanding of the differentiation
hierarchy of hematopoietic cells. The identification of immuno-
phenotypic markers and gene expression profiles correlated with
maturation has enabled researchers to map the expansion of
malignant cells to particular stages of hematopoietic differentiation
[2]. Such characterization has proven invaluable for diagnostic
and prognostic purposes, and continues to provide clues for
pharmacological interventions. Furthermore, the extent of differ-
entiation indicated by the histologic subtype of liposarcoma is the
most important determinant of the clinical outcome for this cancer
type [3–5]. Nevertheless, attempts to categorize solid tumors have
proven difficult due to an incomplete understanding of differen-
tiation pathways from stem cells into mesenchymal and epithelial
tissues. The classifications undertaken so far have been based on in
vitro measurements of genes expressed during the differentiation of
stem cells into mature tissue; this data was then compared to
expression profiles of different tumor subtypes to identify the
maturation stages to which these subtypes correspond [6].
However, such approaches are not yet widely applicable since
the prospective isolation of tissue-specific stem cells has been
possible for only few tissue types, e.g. hematopoietic, mesenchy-
mal, epithelial, and neural tissues ([7] and references therein).
Similarly, in vitro methods of differentiation are available for only a
few histologies [8]. Furthermore, the necessity of an array of
growth factors for in vitro differentiation raises questions about the
similarity of the in vitro model to in vivo processes. Often only a
fraction of cells undergoes differentiation under in vitro conditions,
and currently available methods do not allow isolation of those
cells during the differentiation process from the bulk of unchanged
cells.
An objective categorization of cancers according to maturity
requires a methodology that does not depend on expression data
obtained from in vitro models of differentiation. In this paper, we
develop a novel computational algorithm that assigns a degree of
dissimilarity from stem cells to human cancer subtypes. Our
methodology utilizes gene expression data of tumor subtypes to
construct a phylogenetic tree based on genes differentially
expressed among the subtypes, as well as gene expression data
of stem cells and fully differentiated cells. The resulting phylogeny
provides information about the maturation status of tumor
subtypes and the relationship between them. The results of our
algorithm are conceptually similar to the mapping of cellular
expansion occurring during hematopoietic malignancies to the
differentiation hierarchy of hematopoiesis. Our methodology
allows classification of cancer subtypes according to their
maturation status, to identify genes whose expression correlates
with differentiation, and to discover candidate genes which are
promising therapeutic targets. Our methodology is part of an
increasing literature of mathematical and statistical investigations
of cancer [9–14].
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Phylogenetic tree reconstruction method
Our algorithm uses gene expression data of tumor samples that
have been pathologically classified into subtypes. The expression
data is normalized and then analyzed for differentially expressed
genes, i.e. those genes whose expression in samples from one
tumor subtype differs from the expression in samples from at least
one other subtype. We use these genes to compute the distances
between all pairs of subtypes; the resulting distance matrix is then
used to construct a phylogenetic tree. This construction is repeated
several thousand times using different subsets of genes (of varying
size) to estimate the statistical significance of the branches of the
tree (Fig. 1). We perform a systematic analysis of several methods
and parameters used in our algorithm (see Methods for details).
We find that combining ANOVA and Benjamini-Hochberg with a
p-value of 0.01 gives good and robust results, while the Weighted
Least Squares (WLS) tree reconstruction method works best when
combined with the Pearson correlation matrix. Other combina-
tions of methods give similar results and therefore should be tested
in order to have an accurate understanding of a given dataset.
The phylogenetic tree resulting from this analysis contains
information about the relation among subtypes as well as between
subtypes and the root of the tree. The branching points represent
the ‘common ancestors’ of the subtypes that are situated at the
leaves of those branches. If the tree is rooted with expression data of
a primitive cell type such as embryonic or tissue-specific stem cells,
then the subtypes that are located more closely to the root
correspond to types that are more similar to stem cells while the
subtypes that are located farthest away from the root represent the
most dissimilar types. The order of the branching points along the
differentiation course can be interpreted as the ranking in
Author Summary
Gene expression profiling of malignancies is often held to
demonstrate genes that are ‘‘up-regulated’’ or ‘‘down-
regulated’’, but the appropriate frame of reference against
which observations should be compared has not been
determined. Fully differentiated somatic cells arise from
stem cells, with changes in gene expression that can be
experimentally determined. If cancers arise as the result of
an abruption of the differentiation process, then poorly
differentiated cancers would have a gene expression more
similar to stem cells than to normal differentiated tissue,
and well differentiated cancers would have a gene
expression more similar to fully differentiated cells than
to stem cells. In this paper, we describe a novel
computational algorithm that allows orientation of cancer
gene expression between the poles of the gene expression
of stem cells and of fully differentiated tissue. Our
methodology allows the construction of a multi-branched
phylogeny of human malignancies and can be used to
identify genes related to differentiation as well as novel
therapeutic targets.
Normalize (Bioconductor, rma) 
Compute Distance Matrix (R) 
Construct Tree (Phylip) 
Bootstrapping 
  N = 10,000 
Filter Genes, ANOVA FDR < 0.05 (0.01,…) 
Consensus Tree (Phylip/Dendroscope) 
Calculate Averaged Expression Matrix 
Figure 1. Schematic outline of the methodology. The flow chart shows the main steps of the algorithm used to construct a phylogenetic tree of
tumor subtypes. First, the data is normalized using the Bioconductor software. Then ANOVA is used to identify those genes that are differentially
expressed in at least one tumor subtype; we use a False Discovery Rate (FDR) of less than 0.01. Afterwards, the expression of each differentially
expressed gene is averaged across all samples of each subtype. Those average expression levels are then used to compute the distance matrix of the
subtypes, which is in turn utilized to construct a phylogenetic tree using the Phylip or FastME software. To determine the consensus tree, the
phylogenetic construction is repeated 10,000 times using different sets of differentially expressed genes (of varying number). The consensus tree
produced with this bootstrapping approach is visualized with the Dendroscope software.
doi:10.1371/journal.pcbi.1000777.g001
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between stem cells and tumor subtypes are in part caused by
different differentiation status and in part by the abnormal cancer
phenotype. In some situations, the order of the subtypes dictated by
the tree is not unique, resulting from a non-fully balanced tree. For
instance, more than one subtype canbe mappedto exactly the same
point in the ordering according to dissimilarity from stem cells.
Furthermore,thetwosubtypesfarthestawayfrom theroot sharethe
same common ancestor and therefore cannot be distinguished in
their level of dissimilarity. To resolve this conflict, expression data of
a fully differentiated cell type can be included, which unambigu-
ously defines the last branching point in the ranking.
We validate our methodology with three datasets: (i) a dataset
containing gene expression data of acute myeloid leukemia (AML)
samples which are categorized according to the French-American-
British (FAB) classification into classes that mirror maturation
status [2]; (ii) a dataset containing gene expression of breast cancer
samples classified according to estrogen receptor status and Elston
histological grade [15–17]; and (iii) a dataset containing gene
expression data of liposarcoma subtypes which have been analyzed
for their differentiation status by comparing them to an in vitro
differentiation time course [6].
Acute myeloid leukemia (AML) is a clonal disease characterized
by the accumulation of myeloid progenitor cells in blood and bone
marrow [18]. AML results from changes in transcription factor
regulation that lead to a disruption of normal cellular differenti-
ation. AML is classified into seven distinct subtypes depending on
the morphology and differentiation status of tumor cells:
dedifferentiated, myeloblastic, myeloblastic with maturation,
promyelocytic, myelomonocytic, monocytic, and erythroleukemic
AML. According to the FAB classification, these subtypes are
denoted by M0, M1, …, and M6, respectively. Since AML is the
result of alterations of the differentiation process, we validate our
approach with a dataset of gene expression of AML patients.
Our leukemia dataset contains gene expression data of 362
AML patients and of 7 patients with unclassified Myelodysplastic
Syndrome (MDS) (see Methods for details of dataset compilation)
(Table 1). To root the AML tree, we use expression data of human
embryonic stem cells (hESC); additionally, we include expression
data of CD34+ hematopoietic cells from both peripheral blood
(CD34 PB) and bone marrow (CD34 BM), human mesenchymal
precursor cells (hESC MPC), as well as fully differentiated
mononuclear cells from peripheral blood (PB) and bone marrow
(BM). The surface glycophosphoprotein CD34 is expressed on
undifferentiated hematopoietic stem and progenitor cells [19] and
is widely used as a marker for less differentiated hematopoietic
cells. We include these two subgroups as a further test of our
methodology since their differentiation status is known. We use
ANOVA to identify those probe sets that are significantly
differentially expressed in at least one subtype as compared to
all other AML subtypes. The analysis identifies 11,105 probe sets
that are differentially expressed among AML subtypes if a false
discovery rate (FDR) [20] of 0.01 is used. Use of this cutoff would
lead us to expect 111 false positives. If we use the Holm correction
method instead [21], which controls the family-wise error rate,
then the number of differentially expressed probe sets decreases to
4,051 (with 0.01 expected false positives). The inclusion of less
significantly differentially expressed genes is a potential source of
noise; however, high cutoffs for significance discard genes that
could be interesting for further analysis. The tradeoff between
these two effects must be examined carefully to choose an
appropriate cutoff. We decided to use a standard cutoff FDR of
0.01 because the tree topology remains stable for large gene sets,
and also a larger number of potentially interesting genes are
included which can be further filtered with other techniques.
The consensus phylogenetic tree based on this data is shown in
Fig. 2. The order of the branching points of the subtypes coincides
with the differentiation stages specified by the FAB classification:
dedifferentiated AML (the M0 subtype) is located close to the stem
cells while myelomonocytic (M4) and monocytic (M5) AML are
located in the most distant leaves of the tree. The inner branching
of the tree is also in accordance with the differentiation status
suggested by the FAB classification (Table 1). The tree topology
specifying the correct order of myeloblastic and promyelocytic
maturation (M2 and M3), however, only has a moderate bootstrap
value because the two subtypes are very similar in maturity. The
branch leading to the erythroleukemic subtype (M6) is relatively
unstable. This could be attributed to the small number of samples
in this subtype or to a possible misclassification or erroneous
diagnosis. Therefore, the position of this subtype in the tree is less
certain than that of other subtypes; this uncertainty decreases the
bootstrap values of the other branches at which this subtype can be
located. All other branches in the tree are very stable under
bootstrapping. Of central importance for the interpretation of the
results is how well the tree captures the observed relationships in
the data. A good measure of this fit is the average percent standard
deviation of the distances between subtypes in the data compared
to the ones in the tree. The Least Squares algorithm minimizes this
score. For the Pearson correlation distance, the mean observed
average percent deviation is 12.05%, which is a reasonable fit for
this distance measure [22]; hence our algorithm produces a
phylogeny which accurately recapitulates the relationships seen in
the data.
We also apply our algorithm to a breast cancer dataset in order
to study the performance of our method using cancers of epithelial
origin. The samples in our dataset were characterized by
immunochemistry methods according to their estrogen receptor
status (ER+ and ER2) and Elston histologic grade (G1, G2, and
G3). We compile a total of 483 unique samples, among which we
find all combinations of ER status and grade (Table 2). The raw
data is analyzed as described in the methods section. We root the
tree with human mesenchymal stem cells and also include samples
of normal breast [23]. Results are shown in Fig. 3. We find 17,966
probes differentially expressed between the subgroups when using
ANOVA with Benjamini-Hochberg correction and a cutoff value
of 0.01. A negative ER status has been shown to correlate with
poor prognosis [24]. Consistent with this observation, our
algorithm places ER-negative subgroups closer to stem cells,
reflecting the more stem-like properties of these aggressive tumors,
while ER+ tumors are placed closer to the normal breast tissue
Table 1. French-American-British (FAB) classification of acute
myeloid leukemia (AML) subtypes and numbers of samples.
FAB class Name of subtype Number of samples
M0 Dedifferentiated 14
M1 Myeloblastic 78
M2 Myeloblastic with maturation 78
M3 Promyelocytic 29
M4 Myelomonocytic 75
M5 Monocytic 78
M6 Erythroleukemic 10
The table shows the names of subtypes as classified by FAB and the numbers of
samples included in our study (see Fig. 2).
doi:10.1371/journal.pcbi.1000777.t001
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higher grade closer to stem cells. Most trees reconstructed with the
different sets of genes have the same topology (bootstrap values
close to 100%), reflecting a very robust phylogeny. We conclude
that our methodology is also able to accurately rank tumors of
epithelial origin according to maturity.
Next we construct a phylogeny of liposarcoma subtypes.
Liposarcoma is the most common type of soft tissue sarcoma
accounting for about 20% of all tissue sarcomas [25]. In 2008,
10,390 new cases of sarcoma were reported in the US [26].
Surgery is the standard care for localized tumors but leads to worse
prognoses in cases of locally advanced or disseminated disease
[27]. Liposarcomas are classified into three biological types
encompassing five subtypes: (i) well-differentiated/dedifferentiat-
ed, (ii) myxoid or round cell, and (iii) pleomorphic liposarcoma,
based on morphological features and cytogenetic aberrations [28].
Although the subtype is the main determinant of clinical outcome
[3,4,29–31], liposarcomas of similar morphology can differ in
response to treatment and in prognosis [27]. Microscopically well-
differentiated liposarcoma is composed of relatively mature
adipocytic proliferation showing significant variation in cell size
and at least focal nuclear atypia. Histologically dedifferentiated
liposarcoma is represented by the transition from well-differenti-
ated liposarcoma to non-lipogenic sarcoma. Both well-differenti-
ated and dedifferentiated liposarcomas contain characteristic ring
or giant marker chromosomes with 12q14-15 amplification.
Myxoid liposarcomas contain uniform round to oval shaped
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Figure 2. A phylogeny of acute myeloid leukemia (AML) subtypes. According to the French-American-British (FAB) classification, AML
samples are classified into seven different types according to their level of differentiation (see Table 1). Expression data from 362 AML patients and7
Myelodysplastic Syndrome (MDS-AML) patients is used to construct a phylogeny of these leukemias. We include expression data of human
embryonic stem cells (hESCs), CD34+ cells from bone marrow (CD34 BM) and peripheral blood (CD34 PB), and mononuclear cells from bone marrow
(BM) and peripheral blood (PB). The differentiation pathway from hESCs to mononuclear cells from peripheral blood is represented in purple, and the
common ancestors of subtypes are shown as pink dots. The bootstrap values of branches are indicated by boxed numbers, representing the
percentage of bootstrapping trees containing this branch. The ranking of AML subtypes identified by the phylogenetic algorithm corresponds with
the differentiation status indicated by the FAB classification. The M6 subtype, represented by only 10 samples in our dataset, has the least stable
branch, leading to lower bootstrap values for those branches where it can alternatively be located.
doi:10.1371/journal.pcbi.1000777.g002
Table 2. Breast cancer subgroups and numbers of samples.
Characterization of subgroup Number of samples
Normal breast tissue (NB CA) 14
ER 2 Grade 3 76
ER 2 Grade 2 27
ER 2 Grade 1 3
ER + Grade 3 84
ER + Grade 2 179
ER + Grade 1 114
The table shows the names of the subgroups contained in the breast cancer
dataset and the numbers of cancer samples as well as healthy tissue samples
included in our study (see Fig. 3).
doi:10.1371/journal.pcbi.1000777.t002
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of small signet-ring lipoblasts in a prominent myxoid stroma.
Round cell tumors are characterized by solid sheets of primitive
round cells with no intervening myxoid stroma. Pleomorphic
liposacoma is a pleomorphic high grade sarcoma containing a
variable number of pleomorphic lipoblasts.
Recently, progress has been made towards a classification of
liposarcoma subtypes utilizing gene expression data. In 2007, a
142-gene predictor was identified which correctly distinguishes
between liposarcoma subtypes and generates a set of differentia-
tion-related genes that may contain candidate therapeutic targets
[27]. In 2008, Matushansky et al. showed that the main
liposarcoma subtypes can be ranked according to their differen-
tiation status by comparing gene expression data of the tumor
subtypes with the genes expressed during normal in vitro
adipogenic differentiation [6]. The ranking generated by the
latter approach is useful for validating our methodology.
Our liposarcoma dataset includes 180 surgical samples that
have been pathologically classified as 61 dedifferentiated, 52 well
differentiated, 26 pleomorphic, 18 round cell, and 23 myxoid
liposarcomas [27,30]. Samples that were likely misclassified were
filtered in previous studies, which is a pre-processing step critical
for the outcome of the algorithm. For an FDR of the ANOVA
filter of 0.01 after correction with the Benjamini-Hochberg
method, we find 13,429 probe sets that are differentially expressed
among the liposarcoma subtypes. Those sets are then used to
construct an unrooted phylogenetic tree. To root the tree, we use
expression data of mesenchymal stem cells and fully differentiated
adipocytes. The resulting consensus tree is shown in Fig. 4a. The
tree topology is stable with bootstrap values larger than 85%.
Based on the consensus tree, the subtypes can be ordered by
increasing dissimilarity from stem cells as dedifferentiated,
pleomorphic, myxoid/round-cell, and well-differentiated liposar-
coma (Fig. 4a). This order coincides with experimental results
based on the gene expression observed during in vitro differenti-
ation published earlier (Fig. 4b) [6]. By setting the p-value
threshold of the Holm correction to 0.01, we obtain 7,290
differentially expressed probe sets; these probe sets generate a tree
topology that is identical to the case described above with
bootstrap values larger than 91.5% (data not shown). When
ER-G3
ER-G2 
ER-G1
ER+G2
ER+G1
Normal
Breast
ER+G3
hESC
hMSC MPC
Bootstrap values (percent)
Branching points from 
differentiation course
Differentiation course
100
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Figure 3. A phylogeny of breast cancer subgroups. The figure shows the consensus tree of breast cancer subgroups. We use expression data of
483 breast cancer samples subdivided as shown in Table 2. The tree is rooted with expression data of human mesenchymal stem cells (hMSCs). We
also include expression data of fully differentiated normal breast tissue. The differentiation pathway from hESC to fully differentiated breast tissue is
indicated in purple, and the pink dots represent the common ancestors of (sets of) subgroups. The boxed numbers specify the bootstrap values of
branches. The phylogeny ranks the breast cancer subtypes according to their dissimilarity from stem cells as ER2 grade 3, ER2 grade 2, ER+ grade 3,
followed by ER2 grade 1, ER+ grade 2 and ER+ grade 1.
doi:10.1371/journal.pcbi.1000777.g003
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embryonic stem cells and the rest of the tree is less stable since
the expression of embryonic stem cells differs considerably from all
other samples (data not shown). To increase the stability of the
tree, it is preferable to root with an outgroup that is relatively
closely related to the investigated samples (in this case, mesenchy-
mal stem cells; see also the section ‘‘Systematic analysis of methods
and parameters’’) [32]. Again we test how well the tree fits the
distance matrix and observe a mean average percent standard
deviation of 11.3%, which has been reported to be a good fit for
the Pearson correlation distance [22]. Therefore, our methodology
is also able to rank liposarcoma subtypes in the correct order
according to their dissimilarity to stem cells.
Since our methodology correctly ranks leukemia, breast cancer,
and liposarcoma samples according to their differentiation status,
we now investigate a larger number of sarcoma subtypes to
A
B
hMSC MPC
DD
PL
MYX
MRC
WD
NF
Day 3 Day 7 Day 10
21 days in vitro differentiation 
Day 14 Day 21 hMSC
Dedifferentiated
liposarcoma
Pleomorphic
liposarcoma
Myxoid/Round
liposarcoma
Well-differentiated
liposarcoma
Fat
Bootstrap values (percent) 100 100
100
85
97
Branching points from 
differentiation course
Differentiation course
Figure 4. A phylogeny of liposarcoma subtypes. (a) The figure shows the consensus tree of liposarcoma subtypes. The tree is rooted with
expression data of human mesenchymal stem cells (hMSC), and expression data of normal fat cells is included as well. The differentiation pathway
from hMSC to normal fat cells is represented in purple. The pink points represent common ancestors of (sets of) subtypes. The boxed numbers
specify bootstrap values of branches. The tree indicates that dedifferentiated liposarcoma is most similar to stem cells, followed by pleomorphic,
myxoid, round-cell, and finally well-differentiated liposarcoma. (b) The figure shows a schematic representation of the correlation of adipogenesis to
liposarcoma differentiation. In [6], human mesenchymal stem cells were differentiated in vitro to produce fat cells, and gene expression was
measured for five different time points during the differentiation. The expression data of four different liposarcoma subtypes was then compared to
the data obtained from the differentiation time course. This comparison identified dedifferentiated liposarcoma as the subtype most similar to stem
cells, followed by pleomorphic, myxoid/round-cell, and well-differentiated liposarcoma. The correspondence between the results of our algorithm
applied to gene expression datasets and these experimentally derived results serves as a validation of our methodology. Adapted from [6].
doi:10.1371/journal.pcbi.1000777.g004
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for therapeutic intervention. The sarcoma dataset includes the 180
liposarcomas discussed above as well as 36 myxofibrosarcomas, 5
pleomorphic malignant fibrous histiocytomas (MFH), 7 lipomas,
and 23 leiomyosarcomas (Table 3) [27,30]. We use expression data
of both mesenchymal stem cells and embryonic stem cells to root
the tree. The consensus tree is shown in Fig. 5. Our methodology
determines that leiomyosarcoma is closest in its differentiation
status to stem cells, followed by MFH and myxofibrosarcoma, and
finally the liposarcoma subtypes (ranked as determined above) and
the benign subtype lipoma. The algorithm also clusters the
subtypes according to tissue of origin, predicting that leiomyosar-
coma branches before all other subtypes, and that MFH and
myxofibrosarcoma have a common ancestor; so do all liposarcoma
subtypes and lipoma. Note that although pleomorphic liposarco-
mas and MFH/myxofibrosarcomas are very similar subtypes at
the level of their genetic copy number aberrations [30], our
algorithm places them in different branches of the tree. This effect
is a result of the phenotype-based nature of our method and is in
accordance with the different tissues of origin of these subtypes.
The tree has a very stable topology with bootstrap values larger
than 0.90 except for the MFH subtype, which exhibits a lower
bootstrap value of 0.60; this value is likely due to the small number
of samples (5) available for this subtype. Note that with the current
dataset, we cannot distinguish between the case in which the
subtype located most closely to stem cells, leiomyosarcoma, is
situated on the adipocytic differentiation path and the case in
which leiomyosarcoma is alternatively located on a branch leading
to fully differentiated tissue of another type. To resolve this
ambiguity, gene expression data of fully differentiated tissue of all
the types giving rise to sarcomas is needed.
We are interested in identifying genes that are related to
adipogenesis, i.e. those genes that correlate with adipocyte
differentiation. To identify such genes, we cluster our list of
differentially expressed genes into a chosen number of groups
depending on their expression pattern in sarcoma subtypes. When
hMSC
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Figure 5. A phylogeny of sarcoma subtypes. The figure shows the consensus tree of sarcoma subtypes. We use expression data of 251 sarcoma
samples classified into the types shown in Table 3. The tree is rooted with expression data of human embryonic stem cells (hESCs). We also include
expression data of human mesenchymal stem cells (hMSC) and of fully differentiated normal adipocytes. The differentiation pathway from hESC to
fully differentiated adipocytes is indicated in purple, and the pink dots represent the common ancestors of (sets of) subtypes. The boxed numbers
specify the bootstrap values of branches. The phylogeny ranks the sarcoma subtypes according to their dissimilarity from stem cells as
leiomyosarcoma, malignant fibrous histiocytoma, myxofibrosarcoma, followed by the liposarcoma subtypes dedifferentiated liposarcoma,
pleomorphic, myxoid/round-cell, and well-differentiated liposarcoma. Lipoma is identified as the subtype most dissimilar from stem cells.
doi:10.1371/journal.pcbi.1000777.g005
Table 3. Sarcoma subtypes.
Tissue Name of subtype Number of samples
Fat Dedifferentiated 61
Pleomorphic 26
Round-cell 18
Myxoid 23
Well-differentiated 52
Lipoma 7
Smooth Muscle Leiomyosarcoma 23
Fibrous Tissue MFH 5
Myxofibrosarcoma 36
The table shows the number of sarcoma subtypes included in our study (see
Fig. 5).
doi:10.1371/journal.pcbi.1000777.t003
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cells (as indicated by the tree in Fig. 4a), the expression of some
genes continuously increases from the less differentiated to the
more differentiated subtypes, while the expression of other genes
decreases or exhibits more complicated patterns (Fig. 6). We
hypothesize that genes whose expression continuously increases or
decreases are possibly related to gain of the features of
differentiation and loss of stem cell-associated functions, even
though this association with maturation may not be causative. To
test this hypothesis, we compare the genes whose expression
increases or decreases along the order of subtypes to previously
published lists of adipocytic differentiation-specific genes [6,31]. In
these two studies, mesenchymal stem cells were differentiated in
vitro into normal fat cells, and the expression profiles of cells were
measured at multiple time points during the differentiation
process. An investigation of genes whose expression levels changed
statistically significantly along the differentiation time course led to
the identification of 67 and 69 genes, respectively [6,31]. These
genes are thought to be related to adipocytic differentiation.
We rank the genes whose expression increases or decreases
along the liposarcoma subtypes (see Fig. 6 for example clusters)
according to the fold change between their expression in hMSC
and in normal fat. Among the 11,105 probe sets obtained by the
ANOVA filtering with FDR of 0.01 after Benjamini Hochberg
correction, the top 25 genes in this ranking are listed in Table 4.
About 64% of these genes coincide with the published lists [6,31].
These results suggest that our methodology is able to identify
differentiation-related genes from the large number of differen-
tially expressed genes. Additionally to the previously identified
genes, our method identified other genes that have not been
associated with adipocytic differentiation (Table 4). For instance,
the protein phosphatase inhibitor 1 (PPP1R1A) is thought to be
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Figure 6. Clusters of gene expression profiles. The figure shows four example groups of differentially expressed genes clustered according to
their expression profiles (see Methods section for details on the clustering algorithm). On the horizontal axis, we show the liposarcoma subtypes
ordered according to the ranking identified by the phylogenetic approach (see Fig. 4a) and in the vertical axis the corresponding standard normalized
average expression values of the subtypes. We also include human embryonic stem cells (hESCs) and normal fat cells. The expression of some genes
continuously decreases from less differentiated samples (hESC, dedifferentiated liposarcoma, …) to more differentiated samples (…, well-
differentiated liposarcoma, normal fat) (a), while the expression of other genes increases (b). Other genes are overexpressed in just a single
liposarcoma subtype (c) or in a subset of subtypes (d). Those genes whose expression continuously increases or decreases are hypothesized to be
related to adipogenesis (see Table 4).
doi:10.1371/journal.pcbi.1000777.g006
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expressed in liver cells; the tyrosine kinase NTRK2 is part of a
signaling pathway leading to neuronal differentiation, and the
metabolism related enzyme system ACACB is exclusively
expressed in adipocyte tissue.
Comparison of tree reconstruction methods to other
algorithms
We compare the results obtained from phylogenetic tree
reconstruction algorithms with other methods of data clustering
and organization such as a simple greedy algorithm (in which
subtypes are linearly ordered by their distance from hESC), self-
organizing maps (SOMs), and minimum spanning trees (MSTs) (see
the Methods section for details of the algorithms). When applying
the greedy algorithm to our AML dataset, we find similar results to
those produced by the tree reconstruction analysis (Fig. 7a).
Although the correspondence between the results of this method
and the reconstructed phylogenetic tree is very good, the former
only contain information of a linear organization, as opposed to the
richer information that can be extracted from the tree topology and
branch lengths. An example of a self-organizing map (SOM)
algorithm applied to the AML dataset is shown in Fig. 7b. Subtypes
that areknown tobe similar aremappedclose togetheron the grid –
e.g. human embryonic stem cells (hESC), mesenchymal stem cells
(MSC), and samples with markers of poor differentiation (BMCD34
and CD34PB). Unfortunately, the overall organization of a SOM
stronglydependsonthe shape andsize ofthegrid,makingitdifficult
to interpret the results in a robust and useful way for our purposes.
Finally, we calculate a minimum spanning tree (MST) for the AML
dataset (Fig. 7c). This algorithm accurately reproduces the
reconstructed tree found with our original method, with the
exception of mesenchymal stem cells being placed at the edge of the
tree (instead of embryonic stem cells).
Systematic analysis of methods and parameters
We compare the different methodologies implemented in our
algorithm for each step of the analysis in order to identify those
methods and parameters that perform well in the analysis of our
datasets. We apply our algorithm to all datasets using all
combinations of the following methods and parameters: for
finding differentially expressed genes: ANOVA, Kruskal-Wallis
(KW) and Welch approximation (Welch); two methodologies for
p-value correction: Benjamini-Hochberg (BH) and Holm; two p-
value cutoffs: 0.01 and 0.05; five tree reconstruction and clustering
algorithms: Weighted Least Squares (WLS), Minimum Evolution
(ME), Neighbor-Joining (NJ), FastME, and Average Linkage
(UPGMA); and two distance measures: Pearson correlation and
Euclidean distance. The results of these analyses are shown in Figs.
Table 4. Adipogenesis-related genes.
Gene Symbol Gene Name Fold Change (RMA Log-Ratio)
FABP4
ab fatty acid binding protein 4, adipocyte 352.1 (8.46)
LPL
ab lipoprotein lipase 164.3 (7.36)
ADH1B
ab alcohol dehydrogenase 1B (class I), beta polypeptide 150.1 (7.23)
HBA/B hemoglobin 147.0 (7.20)
ADIPOQ
a adiponectin, C1Q and collagen domain containing 137.2 (7.14)
RBP4
ab retinol binding protein 4, plasma 104.0 (6.70)
GOS2
b G0/G1switch 85.6 (6.42)
FOS v-fos FBJ murine osteosarcoma viral oncogene homolog 78.3 (6.29)
SORBS1
a sorbin and SH3 domain containing 1 72.0 (6.17)
PLIN
ab Perilipin 68.1 (6.09)
PRKAR2B
a PRKAR2B a protein kinase, cAMP-dependent, regulatory, type IIb 53.1 (5.73)
CHRDL1
a chordin-like 1 52.0 (5.70)
APOD
a apolipoprotein D 49.9 (5.64)
PPP1R1A protein phosphatase 1, regulatory (inhibitor) subunit 1A 41.4 (5.37)
GHR growth hormone receptor 41.4 (5.37)
AOC3
ab amine oxidase, copper containing 3 (vascular adhesion protein 1) 40.8 (5.35)
CLEC3B C-type lectin domain family 3, member B 38.1 (5.25)
DPT
a dermatopontin 37.0 (5.21)
NTRK2 neurotrophic tyrosine kinase, receptor, type 2 36.5 (5.19)
PALMD palmdelphin 34.1 (5.09)
ACACB acetyl-Coenzyme A carboxylase beta 32.2 (5.01)
LEP
a leptin 28.8 (4.85)
VWF von Willebrand factor 28.1 (4.81)
TIMP4
b TIMP metallopeptidase inhibitor 4 26.7 (4.74)
COL11A1
ab collagen, type XI, alpha 1 211.7 (23.55)
The table shows 25 genes (represented by 28 probe sets) whose expression continuously increases or decreases from less differentiated to more differentiated samples
as ranked in Fig. 6. The genes are ordered according to their fold change in expression between mesenchymal stem cells and normal fat cells. These genes are related to
adipogenesis. About 64% of those genes have previously been reported in [6] and [27] (marked with a and b, respectively).
also reported by
a Matushansky et al. [6] and
b Sekiya et al. [31].
doi:10.1371/journal.pcbi.1000777.t004
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combinations of parameters show that WLS, Pearson correlation,
and BH with a cutoff value of 0.01 perform accurately in
accordance with the AML (Fig. S1), breast cancer (Fig. S2), and
liposarcoma datasets (Fig. S3).
Note that two main assumptions of the UPGMA algorithm are
not fulfilled by cancer subtype data, namely: all species originate
from a common ancestor and they all have evolved at the same
pace. This issue explains why this method fails to reconstruct the
right tree topologies; for example, in all sarcoma UPGMA
topologies (trees 1 and 4 of Fig. S4), some liposarcoma subtypes
branch together with leiomyosarcoma, which is thought to arise
from smooth muscle tissue.
It has been shown in previous studies that, in general, WLS
performs better than NJ when trees have long external or internal
branches (e.g. [33]). Note also that the use of Euclidean distance
leads to less robust results than the use of Pearson correlation when
trees with long branches are considered. For example, when the
Euclidean distance method is applied to the liposarcoma data, the
dedifferentiated and pleomorphic subtypes cluster together with
the well-differentiated subtype and normal fat (Topology 3 of Fig.
S3). The effect of long branches on the Euclidean distance method
becomes even more pronounced when analyzing the sarcoma data
(Fig. S4); in this case, the least common topologies are observed
only when the Euclidean distance method is used. If distant
subgroups (i.e. hMSC and hMSC MPC) are removed from the
analysis, then most parameter combinations including the
Euclidean distance method favor topology 5. This topology was
previously only observed with the Pearson correlation distance (see
Table in Fig. S4, left).
We do not observe a significant influence of the choice of the
method on the identification of differentially expressed genes.
More important for our data is the choice of the p-value cutoff.
For the sarcoma data, conservative p-value cutoffs favor topology
3 while parameter combinations with Benjamini-Hochberg
adjusted p-values seem to favor topology 5 (Fig. S4). The results
of our study suggest that BH with a cutoff of 0.01 is a good
compromise, but we recommend investigating the effects of using
different cutoff values.
In general, all tree reconstruction methods are very fast,
especially since the number of different tumor subtypes in our
analysis is typically limited. So it is possible to test many
parameters in a reasonable time and we recommend doing so.
Discussion
We have presented a rational methodology to investigate the
dissimilarity between cancer subtypes and stem cells. Our
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Figure 7. Alternate distance based methods applied to acute myeloid leukemia (AML) data. (a) The figure shows the results of a simple
algorithm that sorts the AML subtypes by their distance to hESC. The algorithm uses the same distances as the ones for the phylogenetic tree shown
in Fig. 2. (b) Self-Organizing Maps. The AML subtypes are arranged on a hexagonal grid of 1563 nodes. These nodes are visualized by the small red or
white dots. The colors visualize the difference of neighboring nodes. For example, the light nodes surrounding M4 and M5 show that these subtypes
are similar. MSC and CD34+ peripheral blood, however, show very different expression patterns despite the fact that they are ordered close together
on the map. (c) Minimum Spanning Tree (MST) calculation of the Pearson correlation matrix of the AML dataset.
doi:10.1371/journal.pcbi.1000777.g007
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been classified into histological subtypes as well as expression data
of an ‘evolutionary outgroup’ such as embryonic stem cells, tissue-
specific stem cells, and/or fully differentiated normal cells. The
data of tumor subtypes is used to identify the genes that are
differentially expressed among the subtypes, and those genes,
together with data of the outgroup, allows construction of a
phylogeny of cancers. Our algorithm estimates the statistical
significance of the tree branches by bootstrapping, a repeated tree
construction using a varying number of randomly chosen genes.
The distance between the branching points of the tumor subtypes
and the stem cells specifies their dissimilarity, which is caused in
part by differences in maturity, and ranks the subtypes according
to increasing differentiation. This ranking is then used to identify
genes whose expression continuously changes depending on the
degree of maturation.
Our methodology is validated by being able to correctly
reproduce experimental results concerning the relationship in
differentiation status of liposarcoma, breast cancer and AML
subtypes [2,6,18] and concerning genes related to adipocytic
differentiation [6,31]. Our method is useful for identifying genes
that are overexpressed in some tumor subtypes (Fig. 6c). For
instance, genes whose expression is increased in a particular tumor
type but not in normal tissue-specific stem cells and differentiated
cells may represent candidates for targeted therapy, possibly with
lessened side effects. Interestingly, some of the genes found to be
differentially expressed in only one or a few liposarcoma subtypes
can be targeted by currently available drugs. It will be an
important next step to test those genes for a causal role in
tumorigenesis.
In recent years, bioinformatic tools have been widely used to
analyze the vast amount of data produced experimentally. In
analyses of microarray data, simple algorithms for phylogenetic
tree reconstruction, such as Average linkage (UPGMA) [34],
produce rooted bifurcating trees and are routinely applied to
visualize similarities in gene expression. The most prominent
example for this type of analysis are heatmaps, a graphical
representation of the clustered expression matrix where colors
represent the measured gene intensities; a dendrogram is often
added which shows the bifurcating tree best describing the
differences in gene expression [35]. Another important
application of such algorithms is the clustering of tumor sam-
ples for improving or discovering subtype classifications (e.g.
[36]). Other more sophisticated tree reconstruction algorithms
are only rarely applied to expression data [22,37–42]. The
‘molecular clock’ assumption of UPGMA (specifying that
changes occur at a constant rate, [43]) renders this algorithm
inappropriate for our investigation. Other algorithms such as
Maximum Parsimony, Neighbor-Joining (NJ) [44], or Least-
Squares [45] enable us to root the tree and to estimate the
differentiation status of tumor subtypes by a simple compar-
ison of the lengths between the root of the tree and the
branching points of the leaves. We do not use character-based
methods such as Maximum Parsimony due to the necessity of
artificially discretizing the continuous values of gene expression
intensities.
The estimation of evolutionary distances between tumors from
gene expression data is hindered by the fact that small differences
in the biology of tumors may cause large differences in gene
expression. Examples of such situations are given by genes which
trigger the expression of cascades of other genes [40] and
mutational events affecting the expression of several genes [46].
In a recent paper [46], Park et al. proposed the use of correction
methods that estimate mutational distances from the observed
expression distances. This approach represents an interesting new
avenue to further explore in future work.
The phylogeny of tumor subtypes identified by our methodol-
ogy cannot be used to reconstruct the evolutionary history of a
single tumor sample. The fact that dedifferentiated liposarcomas,
for example, branch earlier than well-differentiated liposarcomas
is not to be taken as evidence that one subtype evolved into the
other. Rather, it specifies the dissimilarity of the bulk of tumor cells
between cancer subtypes from stem cells at the time of
observation. Similarly, our methodology cannot be used to
identify the cell of origin of a tumor type. Both the position of a
subtype in a differentiation-based phylogeny and the similarity of a
subtype to an in vitro differentiation time course provide
information about the bulk of tumor cells only; to determine
whether these cells are produced from tumor stem cells which
arose from cells of similar, earlier or more complete differentiation
stages is outside the scope of this approach. Furthermore, the
ability of a phylogenetic tree to reconstruct evolutionary
trajectories when applied to genetic data rests on the assumption
that the genetic material records the evolutionary history of the
system. In the case of phenotypic information such as gene
expression data, this assumption does not hold, and hence any
information about the origin of the investigated cancer subtypes
cannot be obtained.
The generality of our approach and the extensive availability of
high-quality input datasets (e.g. GEO) makes this methodology a
unique tool to investigate differentiation-related genes and the
relationship in maturity of cancer subtypes. The use of data from
patient samples reduces the problems encountered with in vitro
studies regarding the reproducibility of the results in other systems
and their significance to in vivo situations.
Methods
Dataset compilation
We use gene expression data of sarcoma samples from Singer
et al. [27] and Barrentina et al [30]. The gene expression was
measured on Affymetrix U133a oligonucleotide arrays. The
classification in [27] was performed using unsupervised hierarchi-
cal clustering and an SVM-based supervised classification method.
To root the tree, we use expression data of 17 normal fat samples
from the same study as well as expression data of 3 human
embryonic stem cell lines (hESCs) and 3 hESC derived
mesenchymal precursor lines (downloaded from NCBI Geo [47]
accession number GSE7332 [48]). We use gene expression data of
AML [47] patient samples available within GEO (accession
numbers GSE1159, GSE9476 [49], GSE1729 [50], and
GSE12417 [51]). The breast cancer dataset is also compiled from
Microarray data published in GEO with dataset numbers
GSE7390 [16], GSE2990 [15], GSE3494 [17], and GSE9574
[23]. A problem of micrarray meta-analyses is that the different
dataset sources may introduce a bias. We therefore applied
hierachical clustering to the compiled breast cancer dataset and
did not observe a clustering according to the sources.
Statistical methods and analysis
Data preprocessing. The CEL files are normalized and
summarized with the rma function of Bioconductor 2.2 [52–54]. For
the phylogenetic tree construction and mainly as a strategy to
remove potential noise from the data, we only consider genes that
show significant differences in their expression profiles when
comparing tumor subtypes. These differentially expressed genes
are determined with a one-way ANOVA. In addition, our R
scripts support as alternative methods for finding differentially
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test(…, var.equal=FALSE)) [55] and the Kruskal-Wallis test
(kruskal.test()) [56]. As default cutoff we choose Benjamini-
Hochberg corrected p-values [20] of 0.01. To obtain a
differentiation baseline, we include expression data of normal
fully differentiated tissue and, as an outgroup for the phylogenetic
tree construction, the expression profile of tissue-specific stem cells.
Pairwise distances of the cancer subtypes and baseline samples are
computed with the Pearson Correlation Distance (d=1-p) or the
Euclidean Distance of the average group intensities.
Phylogenetic tree reconstruction methods. The phyloge-
netic trees are reconstructed with several distance-based methods.
The fitch program includes the implementations of the Weighted
Least Squares (WLS) [45] and Minimum Evolution (ME) [57]
methods, neighbor provides the Neighbor-Joining (NJ) [44] and
UPGMA algorithms [34]. Both programs are available in the
Phylip package version 3.67 [58]. WLS and ME are methods
designed to find the tree topology that fits the distance matrix best
by optimization. The difference between these two algorithms is
the optimization criterion. WLS minimizes the sum of squares
error of the distances in the tree (d
T) compared to the ones in the
distance matrix (d):
X
i,j
(di,j{dT
i,j)
(di,j)
2 :
The denominator thus weighs the deviations of d from d
T for
distantly related species less. As we often have very distant in vitro
outgroups in the data, this is an important reason for us to choose
WLS as the default tree reconstruction method. ME uses the same
criterion to fit branch lengths to a given tree topology as WLS, but
returns the topology with the smallest sum of branch lengths, not
the one with the smallest sum of squares error. Another related
method is Balanced Minimum Evolution (BME), implemented in
the FastME program [39]. Both WLS and BME have shown good
performance on microarray data [38]. FastME is orders of
magnitude faster than the Phylip implementation of WLS and thus
suitable for very large datasets. NJ is another computationally very
efficient distance-based tree reconstruction method and also
popular because of its accuracy (e.g. [59]). UPGMA [34] is a
hierarchical clustering algorithm that works in a ‘bottom-up’ way:
at the beginning, all elements form individual clusters which are
consecutively combined until all elements are contained in only a
single cluster. In each iteration, the pair with the smallest distance
is combined into a higher-level cluster and the distance matrix is
updated by calculating the distances to the newly formed cluster.
The strength of the algorithm is twofold: it is computationally very
efficient and it does not depend on the a priori selection of the
number of clusters, in contrast to the k-means or SOMs
algorithms.
Bootstrapping procedure. To assess the statistical signif-
icance of the phylogeny, the reconstruction is repeated 10,000
times with random subsets of the differentially expressed genes.
We draw the bootstrap sample size n from the discrete uniform
distribution on the interval [50, N], where N is the total number of
differentially expressed genes. Then n genes are sampled with
replacement from the set of these N genes. We further bootstrap
the tumor samples to incorporate the uncertainty of tumor
classification. Therefore we sample for each tumor subtype ni
experiments with replacement from the set of the ni experiments of
this subtype. Once a consensus tree is determined, it is rooted and
visualized with Dendroscope version 2.2.2 [60].
Profile clustering. The phylogenetic tree explicitly spec-
ifies the differentiation order in the internal branch nodes. We
then use the order of samples determined by the tree to cal-
culate expression profile clusters with mfuzz [61], a fuzzy c-
means R package commonly used for clustering profiles of time
series. This algorithm is similar to the k-means algorithm and
returns the probabilities that a gene belongs to particular
expression profile cluster. As in the k-means algorithm, the
number of expression profile clusters has to be set in advance
and was set to 20 for the clustering of liposarcoma expression
profiles in Fig. 4.
Comparison of our methodology to other clustering and
dimension-reduction methods
Greedy ordering of subtypes. We use a naı ¨ve greedy
algorithm in which subtypes are linearly ordered by their distance
from hESC. The distance calculation and the bootstrapping are
equivalent to the ones used by the phylogenetic tree
reconstruction. Bootstrap values can be interpreted exactly as in
the phylogenetic trees, i.e. peripheral blood samples are positioned
farthest from hESC in all replicates (bootstrap value of 100%),
while M5 is located closest to peripheral blood mononuclear cells
in 82% of the replicates.
Self-Organizing Maps (SOMs) [62]. SOMs are a type of
unsupervised clustering algorithms that map high-dimensional
data into a 2-dimensional grid – typically hexagonal or
rectangular. The number of nodes in the grid must be set in
advance, similarly to the k-means algorithm where the number of
clusters is a predefined variable. The algorithm results in a two-
dimensional map where similar data points tend to cluster
together. SOMs are commonly applied to microarray data to
cluster both genes [63] and tumors [64]. We calculate SOMs with
the original implementation in the SOM_PAK version 3.1 [65] with
the averaged group intensities of all differentially expressed genes
(ANOVA FDR 0.01). We set the topology to hexagonal and
choose the ‘bubble’ neighboring kernel.
Minimum Spanning Trees (MSTs). MSTs are a well-
established concept in graph theory. A spanning tree of a
connected weighted graph G is an acyclic connected subgraph of
G with the same set of vertices as G. A distance matrix can now
be interpreted as a complete graph in which the edge weights
correspond to the distances. The MST is the spanning tree that
connects all vertices of G with the smallest sum of edge weights.
MSTs have been shown to be useful for clustering and
classification of microarray data [66]. For the MST
calculation we use the spantree function of R, which is an
implementation of Prim’s algorithm [67]. We apply this function
to the Pearson distance matrix calculated again with all
differentially expressed genes. A major disadvantage of this
method is the lack of an established algorithm to find consensus
MSTs for the resulting trees after bootstrapping, in contrast to
phylogenetic trees where the availability of a wide range of
methods and implementations makes it easy to summarize
bootstrap results (e.g. [68,69]). Furthermore, there are no
ancestral states (inner nodes) in an MST, as opposed to
phylogenetic trees where subtypes are leaves in the tree and
other nodes are created as ancestral states.
Availability
The R code and the compiled AML dataset are available from
the authors upon request. A user-friendly GUI that supports most
of the methods described in this paper is available as Plugin for
MAYDAY [70].
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Figure S1 Acute myeloid leukemia (AML) consensus tree
topologies. The trees in this figure correspond to all 38 topologies
of the bootstrap consensus trees of 120 different combinations of
parameters (see Methods for details). Topology 7 is the one
produced by our default parameter combination: ANOVA, BH,
p-value cutoff 0.1 and WLS with Pearson correlation distance
(Fig. 2). The table shows the parameters that return the given
topologies. Topology 7, for instance, is only observed with the
Pearson correlation distance, and topologies 8, 13, 17, 25, 31, 33
and 37 are reconstructed only by the UPGMA algorithm.
Found at: doi:10.1371/journal.pcbi.1000777.s001 (0.64 MB EPS)
Figure S2 Breast cancer consensus tree topologies. The figure
shows the ten different consensus trees we obtain by applying 60
different parameter combinations to the breast cancer dataset. The
tree topologies resulting from the UPGMA algorithm and the
Euclidean distance (2, 4, 5, 7, 8, 9) are unable to identify the right
order of subtypes. The remaining parameters do not have such a
strong effect when using this dataset (Topologies 1, 3, 6, 10):
EP+G1 is always the most differentiated subtype and EP-G3 is
always closest to stem cells. Topologies 1 and 6 are favored by NJ
and FastME, while topology 3 is favored by Fitch and ME.
Found at: doi:10.1371/journal.pcbi.1000777.s002 (0.62 MB EPS)
Figure S3 Liposarcoma consensus tree topologies. This figure
shows the four different topologies of the consensus trees of 120
different parameter combinations. Topology 2 corresponds to our
default parameter combination (Fig. 4a). The table shows that this
topology is not observed when the Euclidean distance is chosen.
UPGMA also never returns this topology. The numbers show that
other parameters have little or no effect on the analysis of this data.
Found at: doi:10.1371/journal.pcbi.1000777.s003 (0.31 MB EPS)
Figure S4 Sarcoma consensus tree topologies. This figure shows
all eight different consensus trees we obtain by applying 120
different parameter combinations to the sarcoma data. Topology 5
is the one produced by our default parameter combination (see
Fig. 5) while topology 3 is the same but with the order of DD and
PL switched. The numbers in the table show again that these
topologies are never observed when the Euclidean distance is
chosen. FastME and NJ favor topology 3 while WLS and ME
favor topology 5. Conservative p-value cutoffs such as Holm 0.01
seem to favor topology 3. Again, UPGMA never produces these
topologies. The choice of the distance measure is the biggest
determinant of the tree topology.
Found at: doi:10.1371/journal.pcbi.1000777.s004 (0.57 MB EPS)
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